BHVN Borrow Cost Explodes 1,042% in a Week as Retail Attention Surges

BHVN cost to borrow hit 6.43% on October 28, up from 0.54% just two days earlier. That is a 1,042% rise in one week, and the sharpest move in the lending market for months on a stock already carrying 13.5% of its free float short.

The Borrow Market

The cost jump is the standout. From September through mid-October, BHVN borrow cost sat in a narrow band of 0.41% to 0.62%. On October 26 it was still 0.54%. By October 28 it had reached 6.43%.

Availability remains loose for now. At 2,749%, there are roughly 27 shares available to borrow for every one already lent out. That cushion explains why short interest has not collapsed yet, falling only 6.1% over the past month to 17.87 million shares. But the borrow cost spike tells you the price of putting on or maintaining a short position just changed materially.

The Retail Surge

At the same moment the borrow market shifted, retail attention jumped. Wikipedia views and ORTEX pageview data as of October 25 placed BHVN's retail attention 3.9 standard deviations above its 90-day average. That is not routine noise.

The stock is up 32.1% over the past week. Its closest peers gained a median of 5.6% over the same period. Something specific moved BHVN, and the attention data confirms it reached beyond institutional desks.

Analysts and the Upcoming Print

RBC Capital raised its price target to $22 from $19 on October 23, while keeping a Sector Perform rating. The stock closed at $15.52 on October 28, so the mean analyst target of $22.93 implies roughly 48% upside from current levels, though Morgan Stanley holds Overweight and B of A Securities carries Underperform.

Earnings land on November 12, 14 days away. The four most recent quarterly prints all produced negative one-day moves, ranging from flat to down 6.7%. At the current price and short base, the options market is also flagging caution. The put-call ratio has climbed to 0.25, roughly 1.7 standard deviations above its 20-day mean, and has held elevated for the past week.

What to Watch

The borrow cost curve is the near-term tell. If availability tightens meaningfully from 2,749% while cost holds above 5%, covering pressure on the 13.5% short base could amplify any positive move into the November 12 print. The FDA acceptance of the troriluzole filing, with a first-quarter 2027 PDUFA date, is the pipeline event the bull case rests on. The bear case points to the partial clinical hold on opakalim and limited near-term catalysts beyond that.

Data summary:

• Cost to borrow: 6.43% (Oct 28) vs. 0.54% one week prior, up 1,042%
• SI % of free float: 13.5%, down 6.1% over one month
• Availability: 2,749% (loose)
• Stock up 32.1% past week vs. peer median +5.6%
• Retail attention z-score: 3.9 vs. 90-day average (as of Oct 25)
• Put-call ratio: 0.25, approximately 1.7 standard deviations above 20-day mean
• Next earnings: November 12, 2026
• Mean analyst price target: $22.93